BioLoomics

Prior to joining BioLoomics in 2021 Bill was CEO of a start-up focused on Alzheimer’s disease and CSO of a Boston-based company offering fund-raising services to early-stage entrepreneurs. At BioLoomics, Rachel is focused on optimizing and scaling library production to more efficiently identify drug candidates. Nick Saccomano joins the BioLoomics board of directors with over 35 years of research, development, and management experience across a multitude of therapeutic areas. Our mission is to make safer, more effective cancer therapeutics. BioLoomics’ goal is to make a degrader from an antibody in one month. BioLoomics closed a $575,000 round of pre seed extension funding on May 11, 2021.. MK has nearly ten years of experience in protein therapeutics. Jeremy operates at the intersection of mechanical and electrical engineering and data analysis with an emphasis on biological data sets.